Compare · CTLT vs JNJ
CTLT vs JNJ
Side-by-side comparison of Catalent Inc. (CTLT) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CTLT and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $546.90B, about 32.0x CTLT ($17.10B).
- JNJ has hit the wire 28 times in the past 4 weeks while CTLT has been quiet.
- Both have 25 recent analyst ratings on file.
- Company
- Catalent Inc.
- Johnson & Johnson
- Price
- $63.49+0.02%
- $227.17-1.20%
- Market cap
- $17.10B
- $546.90B
- 1M return
- -
- -6.93%
- 1Y return
- -
- +45.51%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2014
- News (4w)
- 0
- 28
- Recent ratings
- 25
- 25
Catalent Inc.
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest CTLT
- Catalent Announces New Board Appointments
- SEC Form 15-12G filed by Catalent Inc.
- Lennox International Set to Join S&P 500 and BILL Holdings to Join S&P MidCap 400
- Group Pres. Pharma & Consumer Gennadios Aristippos returned 135,286 shares to the company and was granted 21,562 shares, closing all direct ownership in the company (SEC Form 4)
- Group President, Biologics Mcerlane David returned 47,730 shares to the company and was granted 11,426 shares, closing all direct ownership in the company (SEC Form 4)
- Chief Accounting Officer Hatzfeld Michael returned 16,676 shares to the company and was granted 3,144 shares, closing all direct ownership in the company (SEC Form 4)
- SVP, Quality & Reg. Affairs Gunther Scott returned 52,573 shares to the company and was granted 12,938 shares, closing all direct ownership in the company (SEC Form 4)
- SVP, General Counsel, CCO Ferraro Joseph Anthony was granted 14,265 shares and returned 38,232 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Stahl Jack L returned 47,984 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Ryan Michelle R returned 10,835 shares to the company, closing all direct ownership in the company (SEC Form 4)
Latest JNJ
- Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations
- Johnson & Johnson filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 4 filed by Director Woods Eugene A.
- SEC Form 4 filed by Director West Nadja
- SEC Form 4 filed by Director Weinberger Mark A
- SEC Form 4 filed by Director Pinto Daniel E
- SEC Form 4 filed by Director Morikis John G
- SEC Form 4 filed by Director Mcclellan Mark B.
- SEC Form 4 filed by Director Joly Hubert
- SEC Form 4 filed by Director Johnson Paula A